Research Protocols / Growth Axis
Tesamorelin research protocols: the GHRH analogue with a clinical record
Tesamorelin is unusual in this catalogue: a GHRH analogue with completed phase III trials and a regulatory approval history in another jurisdiction. That gives the research literature an unusually solid foundation.
Where most compounds in this catalogue rest on rodent data and mechanistic inference, tesamorelin has a completed clinical development programme behind it. It was studied extensively in HIV-associated lipodystrophy, reaching phase III with published outcome data on visceral adipose tissue. For a researcher, that means the pharmacology is characterised to a standard the rest of the growth-axis field rarely reaches.
The modification
Tesamorelin is a synthetic analogue of human GHRH 1-44 carrying a trans-3-hexenoyl group attached at the N-terminus. Native GHRH is cleaved rapidly by dipeptidyl peptidase-4 at the N-terminal end, giving a circulating half-life near 7 minutes. The hexenoyl modification sterically obstructs that cleavage, substantially extending stability while preserving GHRH receptor agonism.
Compare across the GHRH family we stock:
| Compound | Basis | Stabilising strategy |
|---|---|---|
| Native GHRH | 44 residues | None, cleaved by DPP-4 within minutes |
| CJC-1295 No DAC | GRF 1-29 fragment | Four amino acid substitutions |
| Tesamorelin | Full GHRH 1-44 | N-terminal trans-3-hexenoyl group |
The full-length versus fragment distinction is worth noting. CJC-1295 truncates to the 29 residues sufficient for receptor activation; tesamorelin retains the complete 44-residue sequence and stabilises it chemically instead.
Reconstitution for a 10 mg vial
Our Tesamorelin ships as a 10 mg lyophilized vial, 99.04% HPLC purity on the current lot. Purity in the 99.0 to 99.3 range is expected for a 44-residue peptide: coupling efficiency compounds across every residue, so long sequences plateau below what a pentapeptide achieves. A 99.04% result on 44 residues represents better synthesis than 99.5% on five.
| Water added | Concentration | Per 0.1 mL |
|---|---|---|
| 2 mL | 5 mg/mL | 500 mcg |
| 5 mL | 2 mg/mL | 200 mcg |
| 10 mL | 1 mg/mL | 100 mcg |
At 44 residues tesamorelin carries more secondary structure than the short peptides in this catalogue, so treat it closer to IGF-1 LR3 than to ipamorelin in handling: swirl rather than shake, and aliquot if more than three access events are expected.
Regulatory note
Tesamorelin's clinical approval history exists in a specific jurisdiction for a specific indication, granted for pharmaceutical-grade product manufactured under regulated conditions. Material supplied as a laboratory reference standard is not that product, carries no Health Canada authorization, and is supplied for laboratory research use only. Our tesamorelin research guide covers the trial literature in more detail.
Sourcing and verification
Purity determines whether a result is reproducible. Every Lumera Labs lot ships with a lot-specific certificate of analysis reporting HPLC-UV purity, and those certificates are published at Lab Results before you order rather than emailed afterward. Orders ship from within Canada in 24 to 48 hours, free over $200 CAD, which removes customs exposure and keeps transit short for temperature-sensitive material.
FAQ
How does tesamorelin differ from CJC-1295?
Both are stabilised GHRH analogues but use different strategies. CJC-1295 No DAC is a 29-residue fragment stabilised by four amino acid substitutions. Tesamorelin retains the full 44-residue GHRH sequence and stabilises it with an N-terminal trans-3-hexenoyl group.
Why is tesamorelin resistant to DPP-4?
Dipeptidyl peptidase-4 cleaves native GHRH at the N-terminus within minutes. The trans-3-hexenoyl group attached at that terminus sterically obstructs the cleavage site while leaving receptor agonism intact.
Why is 99.04% purity considered good here?
Because it is a 44-residue peptide. Synthesis coupling efficiency compounds with each residue, so long sequences plateau lower than short ones. A 99.04% result across 44 residues represents better synthesis than 99.5% across five.
How do I reconstitute a 10 mg vial?
2 mL gives 5 mg/mL, 5 mL gives 2 mg/mL, 10 mL gives 1 mg/mL. At 44 residues it carries more secondary structure than short peptides, so swirl rather than shake and aliquot if more than three access events are expected.
What did the clinical programme measure?
Visceral adipose tissue by CT imaging rather than total body weight, reporting preferential reduction in the visceral compartment. Compartment specificity is mechanistically meaningful because visceral and subcutaneous adipose differ in lipolytic sensitivity and receptor expression.
Continue reading